SANTA FE, N.M.--(BUSINESS WIRE)--CytoDyn, Inc. (Pink Sheets:CYDY), as the study sponsor, has been advised of a protocol deviation that occurred in a murine study of dosing and immunogenicity for DNA-based bird flu vaccines. The purpose of the study is to provide empirical validation of the Company’s design for a clinical trial, or to identify any needed modifications to the clinical trial design. CytoDyn’s clinical trial is intended as a preliminary demonstration of safety and efficacy (through the standard marker of protective antibodies) both for the Company’s family of DNA flu vaccines, and for a proprietary method of using such vaccines.
